Toward the latest advancements in cardiac regeneration using induced pluripotent stem cells (iPSCs) technology: approaches and challenges
- PMID: 39175068
- PMCID: PMC11342568
- DOI: 10.1186/s12967-024-05499-8
Toward the latest advancements in cardiac regeneration using induced pluripotent stem cells (iPSCs) technology: approaches and challenges
Abstract
A novel approach to treating heart failures was developed with the introduction of iPSC technology. Knowledge in regenerative medicine, developmental biology, and the identification of illnesses at the cellular level has exploded since the discovery of iPSCs. One of the most frequent causes of mortality associated with cardiovascular disease is the loss of cardiomyocytes (CMs), followed by heart failure. A possible treatment for heart failure involves restoring cardiac function and replacing damaged tissue with healthy, regenerated CMs. Significant strides in stem cell biology during the last ten years have transformed the in vitro study of human illness and enhanced our knowledge of the molecular pathways underlying human disease, regenerative medicine, and drug development. We seek to examine iPSC advancements in disease modeling, drug discovery, iPSC-Based cell treatments, and purification methods in this article.
Keywords: Cardiac regeneration; Regenerative medicine; Signaling pathways; Stem cell-based therapy; iPSC.
© 2024. The Author(s).
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures




Similar articles
-
Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells.Int J Mol Sci. 2024 May 26;25(11):5772. doi: 10.3390/ijms25115772. Int J Mol Sci. 2024. PMID: 38891960 Free PMC article. Review.
-
The march of pluripotent stem cells in cardiovascular regenerative medicine.Stem Cell Res Ther. 2018 Jul 27;9(1):201. doi: 10.1186/s13287-018-0947-5. Stem Cell Res Ther. 2018. PMID: 30053890 Free PMC article. Review.
-
From potential to practice: Overcoming the immaturity of iPSC-derived cardiomyocytes for regenerative medicine.Kardiol Pol. 2025;83(4):417-426. doi: 10.33963/v.phj.104577. Epub 2025 Mar 11. Kardiol Pol. 2025. PMID: 40066964 Review.
-
Induced Pluripotent Stem Cells in Cardiomyopathy: Advancing Disease Modeling, Therapeutic Development, and Regenerative Therapy.Int J Mol Sci. 2025 May 22;26(11):4984. doi: 10.3390/ijms26114984. Int J Mol Sci. 2025. PMID: 40507801 Free PMC article. Review.
-
Transplantation of human induced pluripotent stem cell-derived cardiomyocytes improves myocardial function and reverses ventricular remodeling in infarcted rat hearts.Stem Cell Res Ther. 2020 Feb 21;11(1):73. doi: 10.1186/s13287-020-01602-0. Stem Cell Res Ther. 2020. PMID: 32085809 Free PMC article.
Cited by
-
Stem cells in the treatment of myocardial injury-induced cardiomyopathy: mechanisms and efficient utilization strategies.Front Pharmacol. 2025 Jun 18;16:1600604. doi: 10.3389/fphar.2025.1600604. eCollection 2025. Front Pharmacol. 2025. PMID: 40606613 Free PMC article. Review.
References
-
- Fathi E, Farahzadi R. Mesenchymal stem cells as a cell-based therapeutic strategy targeting the telomerase activity of KG1 Acute myeloid leukemia cells. Acta Medica Iranica. 2022;60(2 SE–Articles). 10.18502/acta.v60i2.8817.
-
- Fathi E, Azarbad S, Farahzadi R, Javanmardi S, Vietor I. Effect of rat bone marrow derived-mesenchymal stem cells on Granulocyte differentiation of mononuclear cells as Preclinical Agent in Cellbased Therapy. Curr Gene Ther. 2022;22(2):152–61. 10.2174/1566523221666210519111933. 10.2174/1566523221666210519111933 - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources